https://go.evvnt.com/1034443-0?pid=5248 Wyndham Boston Beacon Hill
5 Blossom Street
Boston, Massachusetts 02114
Lectures & Conferences
Acute Respiratory Distress Syndrome (ARDS) is a growing and concerning unmet medical need with no effective therapeutic, and a serious medical burden in a world with or without COVID-19. Bringing industry together to consolidate the last 18 months of clinical and translational data, the 2nd ARDS Drug Development Summit is the only translational conference for drug developers to leverage the large homogeneous populations of COVID ARDS.
This is a unique opportunity for you to finally advance clinically successful therapeutics past historical failures and understand pathological differences in lung failure across COVID-ARDS and non-COVID ARDS; to identify intervention points to drive functional change in disease, and evaluate lessons learned from clinical trial design to inform the best fit for your therapeutic approach.
Join us in Boston and meet over 80+ of your peers including Mesoblast, Healios, BioMarck, Gen1E Lifesciences, Apeptico, Edesa Biotech, and many more, to benchmark your modality and approach against the clinical landscape, get exclusive access to unpublished data, and network with senior experts across multiple therapeutic avenues. Leave this meeting with a clear understanding of your preclinical expansion opportunity and how to develop your research against its market opportunity in this pressing area of drug development.
Conference + 2 Workshops - Industry Pricing: USD 3497.0,
Conference + 1 Workshop - Industry Pricing: USD 3048.0,
Conference Only - Industry Pricing: USD 2599.0,
Conference + 2 Workshops - Academic Pricing: USD 2897.0,
Conference + 1 Workshop - Academic Pricing: USD 2548.0,
Conference Only - Academic Pricing: USD 2199.0,
Conference + 2 Workshops - Vendor Pricing: USD 4297.0,
Conference + 1 Workshop - Vendor Pricing: USD 3748.0,
Conference Only - Vendor Pricing: USD 3199.0
Speakers: Alistair Wheeler, Chief Medical Officer, BioMarck Pharmaceuticals, Alpha A. Fowler, Professor, Virginia University, Aurelia De Pauw, Senior Vice President - Clinical Programs and Medical Affairs, Tetra Bio-Pharma, Axel Vater, Founder and Chief Scientific Officer, Aptarion Biotech, B. Taylor Thompson, Professor of Medicine, Massachusetts General Hospital Harvard Medical School, Bernhard Fischer, Chief Executive Officer, Apeptico, Brijesh Patel, Clinical Senior Lecturer In Cardiothoracic, Imperial College London, David Ingbar, Professor, University of Minnesota, Fiona Garner, Executive Director Clinical Development and Translational Medicine, Partner Therapeutics, Hardy Tadahisa Kagimoto, Chairman and Chief Eecutive Officer, Healios K.K., Mark Levitt, Chief Scientific Officer, RedHill Biopharma, Lieuwe Bos, Physician, Amsterdam UMC, Par Nijhawan, Chief Executive Officer, Edesa Biotech, Paul Mountford, Director of R and D, Respirogen, Patrik Sinha, Assistant Professor, Washington University, Ritu Lal, Chief Executive Officer, Gen1E Lifesciences, Rudolf Lucas, Professor, Augusta University, Silviu Itescu, Chief Executive Officer, Mesoblast